Identification of Genes Expressed by Human Airway Eosinophils after an In Vivo Allergen Challenge

Background The mechanism for the contribution of eosinophils (EOS) to asthma pathophysiology is not fully understood. Genome-wide expression analysis of airway EOS by microarrays has been limited by the ability to generate high quality RNA from sufficient numbers of airway EOS. Objective To identify, by genome-wide expression analyses, a compendium of expressed genes characteristic of airway EOS following an in vivo allergen challenge. Methods Atopic, mild asthmatic subjects were recruited for these studies. Induced sputum was obtained before and 48h after a whole lung allergen challenge (WLAC). Individuals also received a segmental bronchoprovocation with allergen (SBP-Ag) 1 month before and after administering a single dose of mepolizumab (anti-IL-5 monoclonal antibody) to reduce airway EOS. Bronchoalveolar lavage (BAL) was performed before and 48 h after SBP-Ag. Gene expression of sputum and BAL cells was analyzed by microarrays. The results were validated by qPCR in BAL cells and purified BAL EOS. Results A total of 299 transcripts were up-regulated by more than 2-fold in total BAL cells following SBP-Ag. Mepolizumab treatment resulted in a reduction of airway EOS by 54.5% and decreased expression of 99 of the 299 transcripts. 3 of 6 post-WLAC sputum samples showed increased expression of EOS-specific genes, along with the expression of 361 other genes. Finally, the intersection of the 3 groups of transcripts (increased in BAL post SBP-Ag (299), decreased after mepolizumab (99), and increased in sputum after WLAC (365)) was composed of 57 genes characterizing airway EOS gene expression. Conclusion We identified 57 genes that were highly expressed by BAL EOS compared to unseparated BAL cells after in vivo allergen challenge. 41 of these genes had not been previously described in EOS and are thus potential new candidates to elucidate EOS contribution to airway biology.

[1]  R. Dziarski,et al.  Correction: Peptidoglycan Recognition Protein 1 Enhances Experimental Asthma by Promoting Th2 and Th17 and Limiting Regulatory T Cell and Plasmacytoid Dendritic Cell Responses , 2013, Journal of Immunology.

[2]  R. Dziarski,et al.  Peptidoglycan Recognition Protein 1 Enhances Experimental Asthma by Promoting Th2 and Th17 and Limiting Regulatory T Cell and Plasmacytoid Dendritic Cell Responses , 2013, The Journal of Immunology.

[3]  N. Jarjour,et al.  Anti‐IL‐5 attenuates activation and surface density of β2‐integrins on circulating eosinophils after segmental antigen challenge , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[4]  N. Jarjour,et al.  Human eosinophils release IL‐1ß and increase expression of IL‐17A in activated CD4+ T lymphocytes , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[5]  Lin Ying Liu,et al.  Potent synergistic effect of IL-3 and TNF on matrix metalloproteinase 9 generation by human eosinophils. , 2012, Cytokine.

[6]  S. Royce,et al.  The regulation of fibrosis in airway remodeling in asthma , 2012, Molecular and Cellular Endocrinology.

[7]  L. Boulet,et al.  Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.

[8]  N. Kaminski,et al.  Deletion of cannabinoid receptors 1 and 2 exacerbates APC function to increase inflammation and cellular immunity during influenza infection , 2011, Journal of leukocyte biology.

[9]  Chang H. Kim,et al.  Differential Effects of Peptidoglycan Recognition Proteins on Experimental Atopic and Contact Dermatitis Mediated by Treg and Th17 Cells , 2011, PloS one.

[10]  Q. Hamid,et al.  Remodeling in asthma. , 2011, The Journal of allergy and clinical immunology.

[11]  N. Krug,et al.  Allergen Challenge Increases Anandamide in Bronchoalveolar Fluid of Patients With Allergic Asthma , 2011, Clinical pharmacology and therapeutics.

[12]  R. Homer,et al.  Modern concepts on the role of inflammation in pulmonary fibrosis. , 2011, Archives of pathology & laboratory medicine.

[13]  S. Fukuyama,et al.  The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling , 2011, Nature Medicine.

[14]  D. Postma,et al.  Persisting remodeling and less airway wall eosinophil activation in complete remission of asthma. , 2011, American journal of respiratory and critical care medicine.

[15]  A. Nakane,et al.  Mouse Peptidoglycan Recognition Protein PGLYRP-1 Plays a Role in the Host Innate Immune Response against Listeria monocytogenes Infection , 2010, Infection and Immunity.

[16]  D. Postma,et al.  Airway eosinophilia in remission and progression of asthma: accumulation with a fast decline of FEV(1). , 2010, Respiratory medicine.

[17]  R. Dziarski,et al.  Peptidoglycan recognition proteins protect mice from experimental colitis by promoting normal gut flora and preventing induction of interferon-gamma. , 2010, Cell host & microbe.

[18]  Lin Ying Liu,et al.  Human Airway Eosinophils Respond to Chemoattractants with Greater Eosinophil-Derived Neurotoxin Release, Adherence to Fibronectin, and Activation of the Ras–ERK Pathway When Compared with Blood Eosinophils , 2010, The Journal of Immunology.

[19]  Deborah A Meyers,et al.  Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. , 2010, The Journal of allergy and clinical immunology.

[20]  W. Busse,et al.  A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. , 2010, The Journal of allergy and clinical immunology.

[21]  J. Rodriguez-Barbosa,et al.  Hvem/light/btla/cd160 Cosignaling Pathways as Targets for Immune Regulation , 2009 .

[22]  S. Willsie.  Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .

[23]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[24]  R. Xavier,et al.  Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43 , 2009, Nature.

[25]  K. Buckland,et al.  Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. , 2009, American journal of respiratory and critical care medicine.

[26]  P. Weller,et al.  Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially , 2008, Journal of leukocyte biology.

[27]  H. Kita,et al.  A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. , 2008, The Journal of allergy and clinical immunology.

[28]  W. Busse,et al.  Up-Regulation and Activation of Eosinophil Integrins in Blood and Airway after Segmental Lung Antigen Challenge1 , 2008, The Journal of Immunology.

[29]  A. Vannacci,et al.  Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs , 2008, Journal of cellular and molecular medicine.

[30]  Lin Ying Liu,et al.  Generation of Th1 and Th2 Chemokines by Human Eosinophils: Evidence for a Critical Role of TNF-α1 , 2007, The Journal of Immunology.

[31]  G. Georgiev,et al.  Cytotoxic T lymphocytes carrying a pattern recognition protein Tag7 can detect evasive, HLA-negative but Hsp70-exposing tumor cells, thereby ensuring FasL/Fas-mediated contact killing. , 2007, Blood.

[32]  S. Werner,et al.  Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System , 2007, Science.

[33]  T. Sugiura,et al.  Chemotaxis of Human Peripheral Blood Eosinophils to 2-Arachidonoylglycerol: Comparison with Other Eosinophil Chemoattractants , 2006, International Archives of Allergy and Immunology.

[34]  Lin Ying Liu,et al.  Human airway and peripheral blood eosinophils enhance Th1 and Th2 cytokine secretion , 2006, Allergy.

[35]  E. Israel,et al.  Effects of allergen challenge on airway epithelial cell gene expression. , 2005, American journal of respiratory and critical care medicine.

[36]  Lin Ying Liu,et al.  IL-5 and Granulocyte-Macrophage Colony-Stimulating Factor Activate STAT3 and STAT5 and Promote Pim-1 and Cyclin D3 Protein Expression in Human Eosinophils1 , 2004, The Journal of Immunology.

[37]  K. Waku,et al.  2‐Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL‐1 human eosinophilic leukemia cells and human peripheral blood eosinophils , 2004, Journal of leukocyte biology.

[38]  S. Orkin,et al.  A Critical Role for Eosinophils in Allergic Airways Remodeling , 2004, Science.

[39]  Lin Ying Liu,et al.  Expression of interleukin-5- and granulocyte macrophage-colony-stimulating factor-responsive genes in blood and airway eosinophils. , 2004, American journal of respiratory cell and molecular biology.

[40]  T. Hudson,et al.  Functional classes of bronchial mucosa genes that are differentially expressed in asthma , 2004, BMC Genomics.

[41]  S. Phipps,et al.  Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.

[42]  M. D'Andrea,et al.  A novel serine protease predominately expressed in macrophages. , 2003, The Biochemical journal.

[43]  I. Grzelewska-Rzymowska,et al.  [Airway remodeling in asthma]. , 2003, Pneumonologia i alergologia polska.

[44]  Lin Ying Liu,et al.  Decreased Expression of Membrane IL-5 Receptor α on Human Eosinophils: I. Loss of Membrane IL-5 Receptor α on Airway Eosinophils and Increased Soluble IL-5 Receptor α in the Airway After Allergen Challenge1 , 2002, The Journal of Immunology.

[45]  T. Out,et al.  Allergen‐induced bronchial inflammation in house dust mite‐allergic patients with or without asthma , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[46]  L. Boulet,et al.  Lower airway inflammatory responses to repeated very‐low‐dose allergen challenge in allergic rhinitis and asthma , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[47]  M. Selsted,et al.  Isolation, Characterization, and Antimicrobial Properties of Bovine Oligosaccharide-binding Protein , 2002, The Journal of Biological Chemistry.

[48]  S. Phipps,et al.  Microarray analysis of eosinophils reveals a number of candidate survival and apoptosis genes. , 2001, American journal of respiratory cell and molecular biology.

[49]  K. Matsumoto,et al.  Gene expression screening of human mast cells and eosinophils using high-density oligonucleotide probe arrays: abundant expression of major basic protein in mast cells. , 2001, Blood.

[50]  Lin Ying Liu,et al.  The relationship of sputum eosinophilia and sputum cell generation of IL-5. , 2000, The Journal of allergy and clinical immunology.

[51]  M. Kurosawa,et al.  Cloning and tissue distribution of a novel serine protease esp-1 from human eosinophils. , 1998, Biochemical and biophysical research communications.

[52]  W. Busse,et al.  The immediate and late allergic response to segmental bronchopulmonary provocation in asthma. , 1997, American journal of respiratory and critical care medicine.

[53]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[54]  W. Busse,et al.  Increased airway inflammation with segmental versus aerosol antigen challenge. , 1993, The American review of respiratory disease.

[55]  P. O'Byrne,et al.  Changes in the cellular profile of induced sputum after allergen-induced asthmatic responses. , 1992, The American review of respiratory disease.

[56]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.